ClinicalTrials.gg
RecruitingNCT07929922ASPIRATEUpdated Nov 10, 2026

Arthrocentesis vs Observation Study for Acute ACL Tears

An interventional study of Knee Aspiration in Anterior Cruciate Ligament (ACL) Tear, sponsored by Ohio State University. Recruiting at 2 sites in United States. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
15 Years to 40 Years
Sex
All
01

Study summary

The ASPIRATE trial is a randomized controlled trial evaluating the effects of pre- and post-operative knee joint aspiration in patients with an ACL injury. The study aims to determine if removing knee joint fluid can mitigate the increasing inflammation after surgery, reduce quadriceps atrophy, improve short-term pain, enhance functional recovery, and lower long-term rates of post-traumatic knee osteoarthritis.

Read the detailed description

While Anterior Cruciate Ligament Reconstruction (ACLR) successfully restores joint stability, patients still face challenges regarding long-term osteoarthritis and lower rates of returning to sports. Traumatic hemarthrosis-the buildup of blood in the joint following an injury and surgery-acts as a toxic agent that triggers cartilage degeneration. Furthermore, it causes arthrogenic muscle inhibition (AMI), which leads to quadriceps muscle shrinkage and abnormal walking patterns. This cycle is often referred to as the "second-hit phenomenon". While draining fluid from the knee (arthrocentesis) before surgery is common, performing repeat drainages after surgery to remove built-up blood is experimental. This study evaluates whether this low-cost, widely available procedure can safely interrupt that destructive cycle.

The main objective of this trial is to intervene in the hemarthrosis process to prevent or reduce the incidence of AMI and cartilage breakdown through pre- and post-operative joint drainage. Secondary objectives include assessing whether the procedure leads to less quadriceps muscle shrinkage, improves short-term pain, enhances leg strength at 3 and 6 months, accelerates return-to-sport rates, and reduces joint wear at a 1-year follow-up.

Eligible participants include individuals aged 15 to 40 years who experienced their injury 30 days or less prior, have a confirmed ACL tear, and have chosen to undergo ACLR using either a quadriceps tendon or bone-patellar tendon-bone autograft. Key exclusion criteria include previous knee or ACL surgery on the same leg, a cortisone injection within the previous 3 months, major multi-ligament repairs done at the same time (such as the MCL, PCL, or PLC), advanced osteoarthritis, pregnancy, or an inability to speak English fluently.

All participants will undergo standard ACLR surgery using their own tissue graft. Clinical assessments are conducted from baseline through 1 year, tracking patient surveys on knee pain, activity levels, and psychological readiness at baseline, 1 week, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year. Physical and imaging steps include measuring thigh circumference with a tape measure at every visit, performing leg strength tests on a special machine at 3 and 6 months, and taking standing knee X-rays with a specialized framing device at the 1-year mark to evaluate joint health.

02

Conditions studied

  • Anterior Cruciate Ligament (ACL) Tear

Browse trials for

Keywords

  • Anterior Cruciate Ligament
  • Aspiration
  • Arthrocentesis
03

In context

Lacerations

174 studies on the registry are indexed under Lacerations; 43 are open to participants now.

This study's planned enrollment of 54 is below the median of 65 across 128 interventional studies indexed under Lacerations.

Browse Lacerations studies →

Lead sponsor

Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 15 -40
  2. Time from injury to aspiration ≤30 days
  3. Patient with a confirmed ACL tear and have elected to have an ACL reconstruction using a quadriceps tendon () or bone-patellar tendon-bone (BPTB) autograft tendon

Exclusion criteria

Exclusion Criteria:

  1. Fear of needles or rejection of arthrocentesis
  2. Previous knee or ACL surgery on the affected knee
  3. Previous cortisone injection in the affected knee within the previous 3 months
  4. Concomitant procedures that involve repair or reconstruction of the medial collateral ligament (MCL), posterolateral corner (PLC) or posterior cruciate ligament reconstruction (PCL)
  5. Osteoarthritis Kellgren-Lawrence grade ≥3.
  6. Cartilage procedures beyond microfracture or chondroplasty
  7. Planned osteotomies or meniscus allograft transplantation (MAT)
  8. Muscular, vascular or neurological diseases that influence rehabilitation or surgery
  9. Current use of prednisone or cytostatic medication
  10. Obesity with a ≥45
  11. Daily smoking
  12. History of illicit drug or alcohol abuse
  13. History of prior infection in knee
  14. History of chemotherapy treatment
  15. History of sickle cell disease
  16. Pregnancy during injury or surgery
  17. No mastery of the English language
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Aspiration

    Each subject that is randomized to this arm will receive a knee aspiration both before and after ACL surgery.

    Procedure: Knee Aspiration

  • No intervention
    No Aspiration

    Each subject that is randomized to this arm will not receive an intervention and will only complete questionnaires.

Interventions

  • ProcedureKnee Aspiration

    Aspiration is a minimally invasive medical procedure in which a sterile needle and syringe are inserted into the intra-articular space of the knee joint to extract excess synovial fluid that is built up around the knee space.

06

What researchers measure

Primary outcomes

  1. Quadriceps peak strength

    The Biodex measurement physical device will be used to measure the isokinetic strength of the quadriceps muscle. The leg is brought from flexion to extension at 60 degrees per second and 300 degrees per second and the maximum force is measured for the quadriceps. This is compared to the contralateral side and expressed in the limb symmetry index (LSI) as the percentage of strength compared to the contralateral side. This is expressed N/m

    Time frame: 3 months and 6 months

Secondary outcomes

  1. Quadriceps atrophy

    The quadriceps circumference of the affected leg is measured in centimeters at 6 and 16 centimeters above the superior pole of the patella and compared to the contralateral side.

    Time frame: 3 and 6 Months

  2. Short-term Pain

    The overall pain in the knee is assessed using a visual analog scale (VAS) questionnaire that is standardized, and this is compared to the preoperative baseline score. The score ranges from 0 to 10 with 0 indicating no pain and 10 indicating worst pain imaginable

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months and 1 year

  3. Patient-reported outcome measures

    The questionnaire subjective International Knee Documentation Committee (IKDC) will be obtained. The score ranges from 0 to 100 with 100 having a normal score and 0 an abnormal score.

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year

  4. Lysholm Score

    The questionnaire Lysholm Score will be obtained. The score ranges from 0 to 100 with 100 having a normal score and 0 an abnormal score.

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year

  5. Forgotten Joint Score

    The questionnaire Forgotten Joint Score will be obtained. The score ranges from 0 to 100 with 100 having a normal score and 0 an abnormal score.

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year

  6. Tegner activity score

    The questionnaire Tegner activity score will be obtained. The score ranges from 0 to 100 with 100 having a normal score and 0 an abnormal score.

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year

  7. Anterior Cruciate Ligament-Return to Sport after Injury (ACL-RSI)

    The questionnaire Anterior Cruciate Ligament-Return to Sport after Injury (ACL-RSI) will be obtained. The score ranges from 0 to 100 with 100 having a normal score and 0 an abnormal score.

    Time frame: 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year

  8. Return to Sports

    Return to sports will be assessed using questionnaires: when they return to sports (months after surgery), if they have reached preinjury level of performance (yes/no) and whether they are fully return to previous level (yes/no).

    Time frame: 3 months, 6 months and 1 year.

  9. Joint space narrowing on radiographs

    Osteoarthritic changes at AP and Rosenberg views at 1 year of the medial and lateral compartment compared to preoperative radiographs measured in absolute millimeters at the narrowest area of the respective compartments

    Time frame: 1 year

  10. Osteoarthritis grade on radiographs

    Osteoarthritic changes at AP and Rosenberg views at 1 year of the medial and lateral compartment compared to preoperative radiographs measured as Kellgren-Lawrence scale (scale from 0 to 4 with 0 indicating no signs of osteoarthritis and 4 indicating end-stage bone-on-bone osteoarthritis)

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Jameson Crane Sports Medicine Institute
    Columbus, Ohio 43230, United States
    Recruiting
    • Michael Keller · Contactmichael.keller@osumc.edu · 614-293-2410
    • Jelle van der List, MD, PhD · Principal investigator
  • Ohio State Outpatient Care Dublin
    Dublin, Ohio 43016, United States
    Recruiting
    • Michael Keller · Contactmichael.keller@osumc.edu · 614-293-2410
    • Jelle van der List, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 46 non-industry interventional studies with no phase under Lacerations, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 72. This study's planned 28 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 12 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Nov 10, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07929922
Responsible party
Jelle van der List, MD PhD MBA (Clinical Assistant Professor, Ohio State University) — Principal investigator
First posted
Nov 10, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Michael Keller
Contact
michael.keller@osumc.edu
614-293-2410
Jelle van der List, MD, PhD
study director · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion